Cahn et al. [16] reported that dapagliflozin reduced the composite of cardiovascular death and hospitalisation for heart failure, with the benefit being numerically greater in patients using baseline GLP-1 RAs (HR: 0.37) compared to non-users (HR: 0.86). The gene discussed is GLP1R; the disease is heart failure.